Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer
Z Yu, Z Liu, X Ouyang, J Du, X Dai, X Chen… - Chinese journal of …, 2012 - Springer
… We discuss the potential of CM maintenance as a treatment for unresectable NSCLC … for
the use of CM herbal formulae as maintenance treatment for patients with unresectable NSCLC. …
the use of CM herbal formulae as maintenance treatment for patients with unresectable NSCLC. …
贝伐单抗治疗晚期非小细胞肺癌的疗效与安全性临床研究进展
胡彬彬， 陈宝清， 卢铀 - 中国肿瘤临床, 2017 - cjco.cn
… plus maintenance bevacizumab in advanced nonsquamous … with pemetrexed in patients
with advanced non- small cell lung … Erlotinib in previously treated non-small cell lung cancer[J]. …
with advanced non- small cell lung … Erlotinib in previously treated non-small cell lung cancer[J]. …
[HTML][HTML] 自体DC/CIK 联合厄洛替尼维持治疗老年晚期非小细胞肺癌的临床疗效分析
何志惠， 洪涛， 苏群豪， 曾江正， 桑圣刚 - 肿瘤防治研究, 2014 - zlfzyj.com
… Abstract:ObjectiveTo evaluate the clinical effects of maintenance … erlotinib on elderly patients
with advanced non-small cell lung cancer ( NSCLC ). Methods Fourty-two elderly patients (…
with advanced non-small cell lung cancer ( NSCLC ). Methods Fourty-two elderly patients (…
表皮生长因子受体酪氨酸激酶抑制剂在野生型进展期非小细胞肺癌治疗中的地位
辛田， 马锐 - 循证医学, 2014 - jebm.cn
… Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, …
Survival benefit with Erlotinib maintenance therapy in patients with advanced nonsmall-cell …
Survival benefit with Erlotinib maintenance therapy in patients with advanced nonsmall-cell …
扶正解毒方联合吉西他滨和顺铂对晚朔非小细胞”, 御泉患者I 细JJL 亚群和血清月.!'瘤标志物的影l 响.
王伟， 金朝晖， 范伏元， 赵四林， 李担… - Progress in Modern …, 2021 - search.ebscohost.com
… tumor markers in patients with advanced non-small cell lung cancer (NSCLC). 80 patients
with advanced … to December 2018 were selected, patients were divided into control group (n=…
with advanced … to December 2018 were selected, patients were divided into control group (n=…
培美曲塞治疗晚期非小细胞肺癌的循证研究
狄宝山 - 2015 - ir.lzu.edu.cn
… and safety of pemetrexed and erlotinib. Methods: Main … versus docetaxel for advanced
NSCLC were included. And … , disease progression, and 1-2 years survival rate for patients with …
NSCLC were included. And … , disease progression, and 1-2 years survival rate for patients with …
厄洛替尼二次治疗晚期非小细胞肺癌患者的临床分析
吴标， 黄诚， 蒋侃 - 中国癌症杂志, 2015 - china-oncology.com
… for erlotinib on treatment of patients with epidermal growth factor receptor mutation in advanced
non-small … Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a …
non-small … Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a …
晚期非小细胞肺癌维持治疗的研究进展
周倩， 谭榜宪 - 中国肿瘤临床, 2021 - cjco.cn
… the efficacy in advanced non-small cell lung cancer (NSCLC), prognosis of patients with
NSCLC … This study reviews the current status of advanced NSCLC maintenance therapy and …
NSCLC … This study reviews the current status of advanced NSCLC maintenance therapy and …
[HTML][HTML] 既往吉非替尼治疗获益的晚期NSCLC 患者再次使用EGFR-TKI 的选择： 原药还是换药？
汤传昊， 李晓燕， 郭万峰， 李俭杰， 秦海峰… - Chinese Journal of …, 2013 - ncbi.nlm.nih.gov
… For advanced non-small cell lung cancer (NSCLC) patients … between patients treated with
Gefitinib and with Erlotinib, no … vs 22.6%, P=0.300, 6), disease control rate (60% vs 74.2%, P=…
Gefitinib and with Erlotinib, no … vs 22.6%, P=0.300, 6), disease control rate (60% vs 74.2%, P=…
[HTML][HTML] 贝伐珠单抗在晚期非小细胞肺癌一线治疗中的研究进展
艾斌， 杨轶璠 - Chinese Journal of Lung Cancer, 2020 - ncbi.nlm.nih.gov
… of front line regimen of advanced nonsqaumous non-small cell lung cancer (NSCLC). It …
reduces the risk of disease progression in patients with advanced non-squamous NSCLC …
reduces the risk of disease progression in patients with advanced non-squamous NSCLC …